Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of roginolisib in advanced or metastatic uveal melanoma
2024-514333-37-00Phase 2Authorised
- Sponsor
- iOnctura
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of roginolisib in intraocular melanoma and eye melanoma (2 arms), sponsored by iOnctura. Primary endpoint: Overall survival. Planned start Dec 2024; status: authorised.
02
Drugs
roginolisib
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on 2024-514333-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514333-37-00.